Reports Q1 revenue $49.0M, consensus $47.25M. “Biote’s (BTMD) first quarter results benefited from efficiencies related to the vertical integration of our 503B manufacturing facility as well as growth in our dietary supplements business,” said Bret Christensen, CEO. “Total first quarter revenue increased 4.7% year-over-year, primarily due to a 25.5% increase in dietary supplements revenue. Procedure revenue decreased 3.6% year-over-year, reflecting reduced commercial effectiveness and a slowdown in new clinic additions. We are focused on driving new clinic growth throughout our network.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTMD:
- Biote Announces Organizational Restructuring for Growth
- Biote Reduces Marc Beer’s Salary Amid Transition
- Biote CEO Bret Christensen, board members buy 260,000 shares of common stock
- Biote price target lowered to $6 from $8 at TD Cowen
- BTMD Buy Rating: Balancing Operational Efficiency and Long-term Growth Amidst Challenges